NPC‐0501 trial on the value of changing chemoradiotherapy sequence, replacing 5‐fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

NPC‐0501 trial on the value of changing chemoradiotherapy sequence, replacing 5‐fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma

Published:2020-06-04 Issue:16 Volume:126 Page:3674-3688
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Anne W. M.¹²^ORCID,Ngan Roger K. C.²³,Ng Wai‐Tong⁴,Tung Stewart Y.⁵,Cheng Ashley A. C.⁶,Kwong Dora L. W.²⁷,Lu Tai‐Xiang⁸,Chan Anthony T. C.⁹,Sze Henry C. K.⁴,Yiu Harry H. Y.³,Wong Frank C. S.⁵,Yuen Kam‐Tong⁶,Chappell Rick¹⁰,Choi Horace C. W.²^ORCID

Affiliation:

1. Department of Clinical Oncology The University of Hong Kong‐Shenzhen Hospital Guangdong China

2. Department of Clinical Oncology The University of Hong Kong Hong Kong Hong Kong

3. Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong Hong Kong

4. Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Hong Kong Hong Kong

5. Department of Clinical Oncology Tuen Mun Hospital Hong Kong Hong Kong

6. Department of Clinical Oncology Princess Margaret Hospital Hong Kong Hong Kong

7. Department of Clinical Oncology Queen Mary Hospital Hong Kong Hong Kong

8. Department of Clinical Oncology Sun Yat‐sen University Cancer Center Guangzhou China

9. Department of Clinical Oncology Prince of Wales Hospital Hong Kong Hong Kong

10. Department of Biostatistics University of Wisconsin Medical School Madison Wisconsin USA

Funder

Hospital Authority

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32972

Reference32 articles.

1. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

2. National Comprehensive Cancer Network.National Comprehensive Cancer Network clinical practice guidelines in oncology: head and neck cancers. Published2019. Accessed October 1 2019.https://www.nccn.org/professionals/physician_gls/default.aspx

3. Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety

5. Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis;BMC Cancer;2024-09-13

2. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer;Radiotherapy and Oncology;2024-07

3. Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiation: What Is Beneficial in Locally Advanced Nasopharyngeal Carcinoma—A 5-Year Comparative Study at a Tertiary Care Center in North India;South Asian Journal of Cancer;2024-06-10

4. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma;Cell Reports Medicine;2024-06

5. Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma;Radiotherapy and Oncology;2024-02